Zheng YC - Search Results

1

An Overview on Screening Methods for Lysine Specific Demethylase 1 (LSD1) Inhibitors.

Zheng YC, Chang J, Zhang T, Suo FZ, Chen XB, Liu Y, Zhao B, Yu B, Liu HM. Zheng YC, et al. Curr Med Chem. 2017;24(23):2496-2504. doi: 10.2174/0929867324666170509114321. Curr Med Chem. 2017. PMID: 28486922 Review.

2

Design, synthesis and antiproliferative activity studies of novel 1,2,3-triazole-dithiocarbamate-urea hybrids.

Duan YC, Zheng YC, Li XC, Wang MM, Ye XW, Guan YY, Liu GZ, Zheng JX, Liu HM. Duan YC, et al. Among authors: zheng jx, zheng yc. Eur J Med Chem. 2013 Jun;64:99-110. doi: 10.1016/j.ejmech.2013.03.058. Epub 2013 Apr 6. Eur J Med Chem. 2013. PMID: 23644193

3

Triazole-dithiocarbamate based selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric cancer cell growth, invasion, and migration.

Zheng YC, Duan YC, Ma JL, Xu RM, Zi X, Lv WL, Wang MM, Ye XW, Zhu S, Mobley D, Zhu YY, Wang JW, Li JF, Wang ZR, Zhao W, Liu HM. Zheng YC, et al. J Med Chem. 2013 Nov 14;56(21):8543-60. doi: 10.1021/jm401002r. Epub 2013 Nov 1. J Med Chem. 2013. PMID: 24131029 Free PMC article.

4

Design, synthesis, and structure-activity relationship of novel LSD1 inhibitors based on pyrimidine-thiourea hybrids as potent, orally active antitumor agents.

Ma LY, Zheng YC, Wang SQ, Wang B, Wang ZR, Pang LP, Zhang M, Wang JW, Ding L, Li J, Wang C, Hu B, Liu Y, Zhang XD, Wang JJ, Wang ZJ, Zhao W, Liu HM. Ma LY, et al. Among authors: zheng yc. J Med Chem. 2015 Feb 26;58(4):1705-16. doi: 10.1021/acs.jmedchem.5b00037. Epub 2015 Feb 6. J Med Chem. 2015. PMID: 25610955

5

Design and synthesis of novel 1,2,3-triazole-pyrimidine-urea hybrids as potential anticancer agents.

Ma LY, Wang B, Pang LP, Zhang M, Wang SQ, Zheng YC, Shao KP, Xue DQ, Liu HM. Ma LY, et al. Among authors: zheng yc. Bioorg Med Chem Lett. 2015 Mar 1;25(5):1124-8. doi: 10.1016/j.bmcl.2014.12.087. Epub 2015 Jan 6. Bioorg Med Chem Lett. 2015. PMID: 25655718

6

A Systematic Review of Histone Lysine-Specific Demethylase 1 and Its Inhibitors.

Zheng YC, Ma J, Wang Z, Li J, Jiang B, Zhou W, Shi X, Wang X, Zhao W, Liu HM. Zheng YC, et al. Med Res Rev. 2015 Sep;35(5):1032-71. doi: 10.1002/med.21350. Epub 2015 May 19. Med Res Rev. 2015. PMID: 25990136 Review.

7

Efficient synthesis of novel antiproliferative steroidal spirooxindoles via the [3+2] cycloaddition reactions of azomethine ylides.

Yu B, Sun XN, Shi XJ, Qi PP, Zheng YC, Yu DQ, Liu HM. Yu B, et al. Among authors: zheng yc. Steroids. 2015 Oct;102:92-100. doi: 10.1016/j.steroids.2015.08.003. Epub 2015 Aug 6. Steroids. 2015. PMID: 26256638

8

Natural Product-Derived Spirooxindole Fragments Serve as Privileged Substructures for Discovery of New Anticancer Agents.

Yu B, Zheng YC, Shi XJ, Qi PP, Liu HM. Yu B, et al. Among authors: zheng yc. Anticancer Agents Med Chem. 2016;16(10):1315-24. doi: 10.2174/1871520615666151102093825. Anticancer Agents Med Chem. 2016. PMID: 26522954 Review.

9

1,2,3-Triazole-Dithiocarbamate Hybrids, a Group of Novel Cell Active SIRT1 Inhibitors.

Zheng YC, Wang LZ, Zhao LJ, Zhao LJ, Zhan QN, Ma JL, Zhang B, Wang MM, Wang ZR, Li JF, Liu Y, Chen ZS, Shen DD, Liu XQ, Ren M, Lv WL, Zhao W, Duan YC, Liu HM. Zheng YC, et al. Cell Physiol Biochem. 2016;38(1):185-93. doi: 10.1159/000438620. Epub 2016 Jan 20. Cell Physiol Biochem. 2016. PMID: 26784898 Free article.

10

TCPs: privileged scaffolds for identifying potent LSD1 inhibitors for cancer therapy.

Zheng YC, Yu B, Chen ZS, Liu Y, Liu HM. Zheng YC, et al. Epigenomics. 2016 May;8(5):651-66. doi: 10.2217/epi-2015-0002. Epub 2016 Apr 22. Epigenomics. 2016. PMID: 27102879 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

292 results

Search Page

Filters